Andrew Williams counsels clients in patent prosecution and patent litigation with a focus in the areas of biotechnology, pharmaceuticals and molecular diagnostics. His more than 17 years of extensive experience ranges from counseling clients regarding the Biologics Price Competition and Innovation Act (“BPCIA”); patent prosecution for large, small, and university clients; and litigation before the Patent Trial and Appeal Board (“PTAB”) and in federal district court. Andrew has represented large pharmaceutical and diagnostic clients, biotechnology startup companies and universities in fields including biological therapeutics, neuropeptides, molecular diagnostics, biosensors, reagents for diagnostics and next-generation sequencing (NGS) and food-based products.

Prior to joining Wolf Greenfield, Andrew was a partner at McDonnell Boehnen Hulbert & Berghoff LLP. He was also a founding member and Chair of the firm’s PTAB Trials Practice Group.

• PTAB Bar Association
  • Member of the Program Committee
• Intellectual Property Owner’s Association 
  
  • Member of the U.S. Patent Law committee (voting) and Pharmaceutical & Biotechnology Issues Committee (non-voting)
• The Richard Linn American Inn of Court
• Federal Circuit Bar Association 
  
  • Member of the Amicus Committee
• American Bar Association 
  
  • Member of the Patents in the Chemical and Life Sciences Committee
• American Association for the Advancement of Science

• Top Author in JD Supra Readers’ Choice 2017 (“Pharmaceutical Industry”) and 2016 (“Patents”)
• Extern, Hon. Richard Linn, U.S. Court of Appeals for the Federal Circuit

Articles

Blogs

• “The State Of Pharma Litigation After The Supreme Court's TC Heartland Case,” Life Science Leader (June 2018)
• “Supreme Court Holds that IPR Proceedings do not Violate Article III or the Seventh Amendment in Oil States v. Greene’s Energy,” MBHB Snippets Alert (April 2018)
• “Motions to Amend at the PTAB after Aqua Products, Inc. v. Matal – What’s a Patent Owner to Do?,” MBHB Snippets Newsletter (Winter 2018)
• “CAFC Shifts the Burden for IPR Claim Amendments from the Patent Owner to the Petitioner,” MBHB Snippets Alert (October 2017)
• “Reports of the Death of the Patent Dance Have Been Slightly Exaggerated,” The Pharma Letter (July 2017)
• “SCOTUS: Supreme Court Lifts Biosimilars by Allowing Early Commercial Marketing Notice,” MBHB Snippets Alert (June 2017)
• “Can SCOTUS solve the biosimilar ‘enigma’?,” Intellectual Property Magazine (March 2017)
• “10 Years Of MedImmune: How Patent Owners Fared,” Law360.com (February 2017)
• “Post-Grant Review Estoppel – Looking Forward by Looking Back at Estoppel in Inter-Partes and Covered-Business-Method Review,” MBHB Snippets Newsletter (Winter 2017)
• “Some Clarity for Biosimilar Applicants,” Intellectual Property Magazine (September 2016)
• “Cuozzo Speed Technologies, LLC v. Lee – Supreme Court Holds Status Quo,” MBHB Snippets Alert (June 2016)
• “Supreme Court Rules District Courts to Have More Discretion in Finding Willful Patent Infringement by Malicious Pirates,” MBHB Snippets Alert (June 2016)
• “The PTAB at the Supreme Court – and the Federal Circuit’s Response,” IP Watchdog (April 2016)
• “Standing Alone – The Current Status of the BPCIA’s Notice of Commercial Marketing,” MBHB Snippets Newsletter (Spring 2016)
• “One Year After In re Cuozzo,” Intellectual Property Magazine Online (March 2016)
• “The PTAB and the Federal Circuit – One Year Later,” MBHB Snippets Newsletter (Winter 2016)
• “5 Questions To Ask About Biosimilars In 2016” Biosimilar Development Online (January 2016)
• “The BIO International Convention in Philadelphia,” Intellectual Property Magazine (September 2015)
• "Amgen v. Sandoz - Did Fed. Circ. Doom The New Biosimilar Approval Pathway?," MBHB Snippets Newsletter (Summer 2015)
• “Biosimilars at the Federal Circuit – Will this be the Last Dance?,” IP Watchdog (June 2015)
• “Biosimilars at the Federal Circuit – Can the Parties Be Compelled to Dance?,” BIOTechNOW (June 2015)
• "First U.S. Biosimilar Application Approved — But What About the Patent Issues?,” iBIO's Biological Quarterly (March 2015)
• “Federal Circuit Sides with Patent Office in First IPR Final Written Decision Review,” MBHB Snippets Alert (February 2015)
• "Just What Does It Take to Amend Claims Before the PTAB?: Lessons Learned From the Board," MBHB Snippets Newsletter (Winter 2015)
• “Teva Pharmaceuticals USA, Inc. v. Sandoz Inc. – U.S. Supreme Court Requires Trial Court’s Findings of Fact in Claim Construction Be Given Deference,” MBHB Snippets Alert (January 2015)
• "How would patent reform legislation in the United States impact the pharmaceutical industry?," Expert Opinion on Therapeutic Patents (November 2014)
• "Patent Reform Legislation Off The Table For Now," BIOTechNOW (June 2014)
• "Senate Judiciary Committee Takes Up, Then Tables, Patent Reform," Today's General Counsel (April 2014)
• "PatentDocs.org: A Rebuttal to The Economist's 'Stalking Trolls'," InnovationAlliance.net (March 2014)

Recent News & Events